Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...
October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (TCT ...
June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS) recently ...
October 25, 2017 — Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) ...
June 6, 2016 — Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel ...
October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND ...
May 18, 2015 — Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its ...
October 7,2014 — Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II ...
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The ...
October 31, 2013 — Amaranth Medical presented positive six-month angiographic results from its first-in-human study of ...